

ASX Code: GSS

28 October 2019

Non-Executive Director Retirement

Genetic Signatures Limited (ASX: GSS, “**Genetic Signatures**” or the “**Company**”) today announced that Non-Executive Director, Mr. Phillip Isaacs has advised he will retire from the Board at the conclusion of the 2019 Annual General Meeting (AGM) on 22 November 2019 in Sydney. The Company thanks Mr. Isaacs for his service and significant contribution to Genetic Signatures.

Mr. Isaacs was appointed to Board of Genetic Signatures in 2003. During his time, he has provided valuable direction to the development of Genetic Signatures domestic business and international commercialisation strategy that is now being realised. Mr. Isaacs played a central role in leading the Company through the IPO in 2015, transitioning the Company from a private to a public entity. He has also held the position of Chairman of the Audit & Risk Committee since listing, in which he provided key oversight in financial reporting, internal control systems, risk management and audit functions.

Genetic Signatures Non-Executive Chairman, Dr. Nick Samaras will assume the position of Chair of the Audit & Risk Committee on an interim basis while Board determines the appropriate candidate for the long term. The Company has commenced an international search for a new Non-Executive Director and will be making an announcement of new board appointments in the near future.

Genetic Signatures Non-Executive Chairman, Dr. Nick Samaras commented:

“On behalf of the Board, I would like to thank Phill for his immeasurable contribution to Genetic Signatures. Phill has served on the Genetic Signatures Board with high distinction for a long period of time and has helped set up the Company for a bright future. I have always valued his counsel and he can be proud of the company he leaves behind. We wish him all the best in his retirement.”

For further information, see our website (www.geneticsignatures.com) or contact us as below:

Dr John Melki

Chief Executive Officer

john.melki@geneticsignatures.com

T: +61 (0)2 9870 7580

Peter Manley

Chief Financial Officer

peter.manley@geneticsignatures.com

About Genetic Signatures Limited: Genetic Signatures is a specialist molecular diagnostics (MDx) company focused on the development and commercialisation of its proprietary platform technology, **3base™**. Genetic Signatures designs and manufactures a suite of real-time Polymerase Chain Reaction (PCR) based products for the routine detection of infectious diseases under the **EasyScreen™** brand. Genetic Signatures’ proprietary MDx **3base™** platform technology provides high-volume hospital and pathology laboratories the ability to screen for a wide array of infectious pathogens, with a high degree of specificity, in a rapid throughput (time-to-result) environment. Genetic Signatures’ current target markets are major hospital and pathology laboratories undertaking infectious disease screening.